Oculis Holding AG
Licaminlimab (OCS-02)
dry eye disease
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for Licaminlimab (OCS-02) in dry eye disease are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“topline results anticipated around late 2026.”